The biotechnology company has officially opened its new Michigan research and production center for the production of spider silk-based fibers, as well as for the company’s polymer research and development program.
On Oct. 23, 2017, Kraig Biocraft Laboratories, a developer of spider silk-based fibers, announced that its previously announced research and production facility in Michigan is now operational. The new facility will enable the domestic production of the spider silk-based fibers, centralize the company’s research and development program for new polymers, and facilitate relocated production operations from Indiana.
Over the next sixty days following this announcement, the company plans to expand the new facility’s production. Additionally, three separate strains of hatching and rearing of silkworms have begun at the site.
According to the company, the opening of the center will be followed by efforts to establish production centers in three overseas locations. During October 2017, the company’s management team is scheduled to meet with senior central government officials in Hanoi, Vietnam, to discuss this production venture. The company is also in communication with another silk-producing country to scale-up its spider silk technology.
Source: Kraig Biocraft Laboratories
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.